Compare Merck & Co., Inc. (MRK) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Taskus Inc — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: Merck & Co., Inc. is far larger — about 485.6× Taskus Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Taskus Inc for 34 Days on average.
| MRK | TASK | |
|---|---|---|
Market Cap | $351.28B | $723.41M |
Volume | 7,969,665 | 201,303 |
Sector | Health | Technology |
52-Week High | $156.43 | $14.69 |
52-Week Low | $82.49 | $4.57 |
Typical Hold Time | 98 Days | 34 Days |
Enterprise Value | $398.04B | $1.09B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
TaskUs trades at $7.89, down 0.88% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin of 8.75%. Valuation metrics appear attractive with P/E of 6.8 and P/S of 0.6. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected. Analyst consensus is bullish with 55% buy ratings and $9.33 price target, representing 18% upside potential.
The stock presents value opportunity with solid profitability and AI services growth offsetting Trust & Safety declines. Key risks include labor cost pressures and client concentration. Positive cash flow generation and institutional accumulation support the bullish case, though technical weakness suggests near-term consolidation may continue before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
